TVTX - Company ID 0001438533
The table below shows Travere Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $490.73M | $233.18M | $145.24M | $109.46M | $131.84M | $198.32M |
| Cost of revenue | $10.34M | $7.74M | $11.45M | $4.42M | $3.82M | $6.13M |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | $7.50M | - | - |
| SG&A |
Travere Therapeutics, Inc. reported annual revenue of $490.73M for fiscal year 2025. That is up 110.5% from $233.18M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $133.59M (FY 2016) to $490.73M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $337.20M |
| $264.12M |
| $265.54M |
| $197.52M |
| $126.28M |
| $135.80M |
| Operating income | -$62.82M | -$323.83M | -$388.14M | -$319.81M | -$199.43M | -$176.16M |
| Income tax | $988.00K | $120.00K | $223.00K | $313.00K | $409.00K | -$19.36M |
| Net income | -$25.55M | -$321.55M | -$111.40M | -$278.48M | -$180.09M | -$169.43M |
| EPS (diluted) | -$0.29 | -$4.08 | -$1.50 | -$4.37 | -$3.01 | -$3.56 |